Better Data for Better Health Geneyx empowers hospitals with best-of-breed diagnostics and genetic data management solutions while providing researchers with a comprehensive AI-based platform for targeted drug research and development For Hospitals For Research Bridging the gap between genetic and clinical data
Start Leveraging The Geneyx Platform

Our Solutions

GA 192px txt UC - Full
AI-Based Genetic Data Analysis

Clinical genomics platform for hospitals and private labs, providing management, analysis and interpretation of genetic data, and clinical reporting

GD 192px txt UC - Full
Secure Genetic Data Storage

Clinical genetic database enabling researchers to securely access and data mine large scale genetic data with associated clinical information

GR 192px txt UC - Full
Targeted Drug Discovery

Drug discovery research suite enabling pharma customers to better interrogate large scale clinical genetic data for identification of novel drug targets

Take Your Genetic Data Further

Advancing Genetic Diagnosis and Research

For Hospitals & Labs

Geneyx Analysis

Double your diagnostic yields while reducing your turn-around time from hours to minutes with our fully customizable clinical genomic platform which support rare disorders, health screening and others

60%
Double your diagnostic yield
95%
Reduce your turn-around time
For Pharma Research

Geneyx Research

Leverage our proprietary technology platform for better Whole Genome Sequencing-based targeted drug discovery, providing interpretation and enrichment of 10x the genome scope

SNP Array
0.3%
Exome
1.5%
Whole Genome Sequencing with Geneyx
18% (Exome + Regulatory Regions + ncRNA)
CUSTOMERS

Discover customer successful stories

img
TESTIMONIALS

What Our Clients Say

NEWS

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

Read More »

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

NEW YORK –A public-private consortium in Israel will collect samples and sequence genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the hopes of discovering new diagnostic and treatment methods. “This is a rare opportunity to thoroughly and consistently document clinical findings of thousands of patients and sequence their whole genome.”Dr. Hagit

Read More »

Request A Demo